Xpovio
Karyopharm reduces employees by 20% as Xpovio sales for blood cancer remain stagnant
SG Tylor
Source – Karyopharm Therapeutics Karyopharm Therapeutics, faced with stagnant sales of its only approved product, Xpovio (selinexor), has announced a ...
Selinexor Receives Fast Track Designation from FDA for Myelofibrosis Treatment
SG Tylor
Source – Karyopharm Therapeutics The FDA has granted fast track designation to selinexor (Xpovio) for the treatment of patients with ...
